Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Chronic myeloid leukemia in 2003].

P Lewalle1, P Martiat

  • 1Laboratoire d'Hématologie Expérimentale et Service d'Hématologie, Institut Jules Bordet, U.L.B.

Revue Medicale De Bruxelles
|December 3, 2003
PubMed
Summary

Imatinib mesylate has transformed chronic myeloid leukemia treatment by targeting the P210 Bcr-Abl fusion protein. Long-term efficacy and evolving therapies like stem cell transplantation require further investigation for optimal treatment strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Sweet's syndrome induced by pegfilgrastim during a myelodysplastic syndrome AREB2: A case report].

La Revue de medecine interne·2018
Same author

Inhibition of P210BCR/ABL Expression in K562 Cells by Electroporation with an Antisense Oligonucleotide.

Leukemia & lymphoma·2016
Same author

[In honor of Professor Philippe Martiat].

Revue medicale de Bruxelles·2015
Same author

Efficacy of lenalidomide in an sAML patient with del 5q relapsing after reduced-intensity allogeneic stem cell transplantation performed in complete remission.

Bone marrow transplantation·2009
Same author

Antileukemic activity of valproic acid in chronic lymphocytic leukemia B cells defined by microarray analysis.

Leukemia·2009
Same author

Reduced intensity conditioning haematopoietic stem cell transplantation with mesenchymal stromal cells infusion for the treatment of metachromatic leukodystrophy: a case report.

Haematologica·2008

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Context:

  • Chronic myeloid leukemia (CML) treatment has been revolutionized by targeted therapies.
  • Imatinib mesylate represents a significant advancement, targeting the specific molecular driver of CML.
  • Understanding the long-term implications and evolving treatment landscape is crucial.

Purpose:

  • To review the current knowledge on chronic myeloid leukemia (CML).
  • To synthesize data on imatinib mesylate's efficacy and limitations.
  • To propose a therapeutic strategy integrating current data and evolving modalities.

Summary:

  • Imatinib mesylate, a physiopathology-based therapy, targets the P210 Bcr-Abl fusion protein's tyrosine kinase activity in CML.
  • While demonstrating impressive initial activity, the long-term efficacy of imatinib mesylate is yet to be determined.
  • Other evolving treatments, including stem cell transplantation and immunotherapy, are also discussed.

Impact:

  • Provides a comprehensive overview of CML management.
  • Highlights the significance of targeted therapy in leukemia treatment.
  • Offers insights into future therapeutic strategies for CML patients.

Related Experiment Videos